Managing underlying ischemia and inflammation in patients with coexistent atrial fibrillation and coronary artery disease is proposed to positively impact and improve quality of life.
This review emphasizes the clinical importance of unmasking and treating coexistent coronary artery disease and inflammation in patients with atrial fibrillation rather than treating the arrhythmia in isolation.
endothelial dysfunctional and inflammation and together with enhanced thrombogenicity and hypercoagulability contribute to micro and macrothrombi throughout cardiovascular system. In a nutshell, the two form a vicious cycle wherein one disease promotes the other. Most AF recommendations focuses on rate/rhythm control and prevention of thromboembolism. Very few studies have discussed the importance of unmasking coexistent CAD and how the treatment of underlying ischemia will impact the burden of AF in these patients. Inflammation and endothelial dysfunction remain central to both disease processes and form a handsome therapeutic target in the management of the two diseases. The relationship between AF and CAD is complex and much more than mere coincidence. The two diseases share common risk factor and pathophysiology. Hence, it is impractical to treat them in isolation. Accordingly, we share the implications of managing underlying ischemia and inflammation to positively impact and improve quality of life among AF patients.
Batta et al. (Thu,) conducted a review in Atrial fibrillation and coronary artery disease. Management of underlying ischemia and inflammation was evaluated. Managing underlying ischemia and inflammation in patients with coexistent atrial fibrillation and coronary artery disease is proposed to positively impact and improve quality of life.